Abstract: Methods of inhibiting the growth of tumors comprising administering chimeric fusion molecules comprising endostatin mutants and all or a portion of anti-Her2 or anti-EGFR antibodies.

Abstract: Methods of inhibiting the growth of tumors comprising administering chimeric fusion molecules comprising endostatin mutants and all or a portion of anti-Her2 or anti-EGFR antibodies.

Abstract: The present invention is directed to fusion proteins having an IL-21 cytokine portion and an anti-CD20 antibody portion, and methods of using such fusion proteins. The invention also provides pharmaceutical compositions and kits utilizing the IL-21-anti-CD20 fusion proteins. In particular, the methods, kits and compositions of the invention are useful in the treatment of cancer and autoimmune diseases.

Abstract: The present invention is directed to fusion proteins having an IL-21 cytokine portion and an anti-CD20 antibody portion, and methods of using such fusion proteins. The invention also provides pharmaceutical compositions and kits utilizing the IL-21-anti-CD20 fusion proteins. In particular, the methods, kits and compositions of the invention are useful in the treatment of cancer and autoimmune diseases.

Abstract: Methods of inhibiting the growth of tumors comprising administering chimeric fusion molecules comprising endostatin mutants and all or a portion of anti-Her2 or anti-EGFR antibodies.

Abstract: Chimeric molecules comprising endostatin and all or a portion of a tumor antigen specific binding molecule for use in treating tumors. The chimeric molecule, includes endostatin, endostatin mutants and variants and an antibody or aptamer specific for a desired tumor antigen. Methods of treating cancer comprise administering the chimeric fusion molecules.

Abstract: Methods and compositions for inducing apoptosis and/or inhibiting proliferation of cells. The method includes exposing the cells to a cytotoxic agent which is made up of a targeting moiety and an avidin moiety wherein the targeting moiety is capable of binding to one or more receptors located on the cells. The invention is based on the discovery that attaching an avidin moiety to non-toxic targeting moieties produces a cytotoxic agent which can be used to treat tumor cells both in vivo and in vitro. The present cytotoxic agent eliminates the use of biotinylated toxic drugs which previously have been conjugated to antibody-avidin targeting vehicles.

Abstract: Compositions for treatment of cancer comprising chimeric fusion molecules that bind to an antigen on a pathogenic cell and to an immune cell. The molecules redirect the immune cells to a pathogenic cell. The purified fusion proteins demonstrated ability to bind antigen on the surface of tumor cells and cell surface receptors on immune cells such as NK cells. The chimeric fusion proteins showed increased cytotoxic activity directed against tumor targets.

Abstract: Chimeric molecules comprising endostatin and all or a portion of an Ig (Ig) molecule are used to treat tumors. A chimeric molecule, including endostatin fused to an Ig domain of an anti-HER2/neu antibody exhibited longer serum half-life and stability than native endostatin. 125I-labeled anti-HER2/neu IgG3-endostatin chimeric molecule and anti-HER2/neu IgG3 preferentially localized to CT26-HER2 tumors. Clearance of anti-HER2/neu IgG3-endostatin was 6 fold faster than that of anti-HER2/neu IgG3 (CLss=0.374 and 0.062 ml/min/kg, respectively), however, the specific tumor radiolocalization indices of anti-HER2/neu IgG3-endostatin were greater than those of anti-HER2/neu IgG3. Anti-HER2/neu IgG3-endostatin inhibited tumor growth more effectively than endostatin alone, anti-HER2/neu IgG3 antibody, or the combination of antibody and endostatin.

Abstract: The present invention relates to chimeric molecules for the stimulation of an anti-tumor immune response to facilitate immune eradication of breast, ovarian and other cancer cells. The chimeric molecules include a binding region which specifically binds to a tumor specific antigen and a chemokine and/or costimulatory ligand. The invention further provides methods for inducing a tumor specific immune response and compositions which can be administered to mammals.

Abstract: Methods and compositions for inducing apoptosis and/or inhibiting proliferation of cells. The method includes exposing the cells to a cytotoxic agent which is made up of a targeting moiety and an avidin moiety wherein the targeting moiety is capable of binding to one or more receptors located on the cells. The invention is based on the discovery that attaching an avidin moiety to non-toxic targeting moieties produces a cytotoxic agent which can be used to treat tumor cells both in vivo and in vitro. The present cytotoxic agent eliminates the use of biotinylated toxic drugs which previously have been conjugated to antibody-avidin targeting vehicles.